Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Management of Rheumatoid Arthritis

Diagnosis and Early Referral

  • The American College of Rheumatology recommends referring patients with suspected persistent synovitis urgently for specialist rheumatologist evaluation, even with normal acute-phase reactants or negative rheumatoid factor, especially when small joints of hands/feet are affected, multiple joints are involved, or symptoms have persisted for ≥3 months 2, 3
  • The British Medical Journal suggests testing for rheumatoid factor in patients with suspected RA who have synovitis 4
  • Consider measuring anti-cyclic citrullinated peptide antibodies in rheumatoid factor-negative patients, particularly when combination therapy is being considered, as recommended by the British Medical Journal 5

Treatment Principles

  • The European League Against Rheumatism recommends that treatment should aim at reaching a target of remission or low disease activity as soon as possible in every patient 6
  • Treatment should be adjusted through frequent monitoring (every 1-3 months) until the target is reached, according to the European League Against Rheumatism 6
  • Rheumatologists should primarily care for patients with RA, with treatment decisions based on shared decision-making between patient and physician, as suggested by the European League Against Rheumatism 6

Pharmacologic Management

  • Methotrexate (MTX) should be part of the first treatment strategy in patients with active RA, according to the European League Against Rheumatism 6
  • The European League Against Rheumatism recommends starting MTX as soon as the diagnosis of RA is made 6
  • When MTX is contraindicated or not tolerated, consider leflunomide, sulfasalazine, or injectable gold as alternative first-line DMARDs, as suggested by the European League Against Rheumatism 6
  • Low to moderately high doses of glucocorticoids added to DMARD therapy provide benefit as initial short-term treatment, according to the European League Against Rheumatism 6
  • The European League Against Rheumatism recommends tapering glucocorticoids as rapidly as clinically feasible 6
  • If treatment target is not achieved with first DMARD strategy and poor prognostic factors are present, consider adding a biologic DMARD, as suggested by the European League Against Rheumatism 6
  • Tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab) are typically the first biologic agents used, and should be combined with MTX, according to the European League Against Rheumatism 6
  • If a first TNF inhibitor fails, consider another TNF inhibitor, abatacept, rituximab, or tocilizumab, as recommended by the European League Against Rheumatism 6
  • For refractory severe RA or when biologics are contraindicated, consider azathioprine, cyclosporine A, or in exceptional cases, cyclophosphamide, as suggested by the European League Against Rheumatism 6

Monitoring and Treatment Adjustment

  • Consider tapering biologic DMARDs in patients who achieve persistent remission, especially if combined with a synthetic DMARD, as recommended by the European League Against Rheumatism 6
  • In cases of sustained long-term remission, cautious reduction of synthetic DMARD dosage may be considered, according to the European League Against Rheumatism 6

Non-Pharmacologic Management

  • Patient education about disease pathophysiology, self-management skills, and joint protection principles improves health outcomes and physical function, as suggested by the Mayo Clinic Proceedings 7
  • Occupational therapy provides benefits through joint protection instruction and prescription of assistive devices, orthotics, and splints, according to the Mayo Clinic Proceedings 7
  • Dynamic exercise programs incorporating both aerobic exercise and progressive resistance training improve fitness and strength without exacerbating disease activity, as recommended by the Mayo Clinic Proceedings 7
  • A multidisciplinary approach involving rheumatologists, nurses, physical and occupational therapists, and psychologists optimizes outcomes, according to the Mayo Clinic Proceedings 7